Floatz logo

LIRAMETOSTAT

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Constellation PharmaceuticalsSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

230 Active assets in the Metastatic Castration Resistant Prostate Cancer (mCRPC) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
RADIUM RA-223
Bayer
Phase 4BB

View all 50 →

Same molecule, other indications

LIRAMETOSTAT is also rated in:

B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
42 / 100
View asset →
cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →